IL17A and psoriasis: Although anti-IL-17A monoclonal antibody does not directly target IL-17F, systemic IL-17A blockade also removed 95% of IL17F-expressing T-cells in psoriasis skin, potentially mediated by IL-23 reduction in dendritic cells (Figure 4C).